2022
Bernardino PN, Smith WA, Galuppo LD, Mur PE, Cassano JM^
Therapeutics prior to mesenchymal stromal cell therapy improves outcome in equine orthopedic injuries.
2018
Cassano JM, Fortier LA, Hicks RB, Harman RM, Van de Walle GR
Equine mesenchymal stromal cells from different tissue sources display comparable immune-related gene expression profiles in response to interferon gamma (IFN)-?.
2018
Cassano JM, Kennedy JG, Ross KA, Fraser EJ, Goodale MB, Fortier LA
Bone marrow concentrate and platelet-rich plasma differ in cell distribution and interleukin 1 receptor antagonist protein concentration.
2018
Cassano JM, Schnabel LV, Goodale MB, Fortier LA
Inflammatory licensed equine MSCs are chondroprotective and exhibit enhanced immunomodulation in an inflammatory environment.
2018
Cassano JM, Schnabel LV, Goodale MB, Fortier LA
The immunomodulatory function of equine MSCs is enhanced by priming through an inflammatory microenvironment or TLR3 ligand.
2017
Hill JA, Cassano JM, Goodale MB, Fortier LA
Antigenicity of mesenchymal stem cells in an inflamed joint environment.
2017
Lang HM, Schnabel LV, Cassano JM, Fortier LA
Effect of needle diameter on the viability of equine bone marrow derived mesenchymal stem cells.
2016
Staiger EA, Tseng CT, Miller D, Cassano JM, Nasir L, Garrick D, Brooks SA, Antczak DF
Host genetic influence on papillomavirus-induced tumors in the horse.
2015
Cassano JM, Schnabel L V, Betancourt AM, Antczak DF, Fortier LA
Mesenchymal Stem Cell Therapy: Clinical Progress and Opportunities for Advancement
2015
Pezzanite LM, Fortier LA, Antczak DF, Cassano JM, Brosnahan MM, Miller D, Schnabel LV
Equine allogeneic bone marrow-derived mesenchymal stromal cells elicit antibody responses in vivo.